Skip to main content
Intermediate Technical IVT

WES

Also written as: WES — whole exome sequencing

Whole exome sequencing that analyzes all protein-coding regions of the genome to identify cancer-related mutations.

Full Definition

Whole exome sequencing (WES) is a genomic technique that selectively sequences the exonic regions of the genome, which represent approximately 1-2% of the total genome but contain roughly 85% of known disease-causing variants. In cancer genomics, WES is used to identify somatic and germline mutations in protein-coding genes that may contribute to tumorigenesis, treatment response, or hereditary cancer predisposition. This approach provides comprehensive coverage of coding regions at a lower cost than whole genome sequencing, making it an attractive option for clinical applications. WES typically achieves high depth of coverage across targeted regions, enabling detection of low-frequency variants and copy number alterations in exonic sequences.

Usage

Usage note: Always spell out on first use in patient-facing documents.

In Context

  • "WES identified several novel mutations in DNA repair genes." — Research manuscript
  • "The laboratory offers WES as part of their hereditary cancer testing panel." — Clinical service description

Also known as

whole exome sequencing exome sequencing

Contrasted with

WGS targeted sequencing

Don't confuse with

WGS RNA-seq

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON